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Abstract
Background:  It is known that during normal pregnancy and after immunotherapy blocking
antibodies are developed, these antibodies inhibit mixed lymphocyte reaction and are also anti-
mitogenic in nature. Mixed lymphocyte reaction blocking antibodies are specific to the husband's
lymphocytes. In the present study an attempt has been made to characterize the mixed lymphocyte
reaction blocking antibodies in normal pregnancy and in women with recurrent spontaneous
abortion after immunotherapy.
Methods: Serum was obtained from women of different gestational windows of pregnancy (Ist,
IInd, IIIrd trimesters and post delivery period of normal pregnancy), recurrent spontaneous
aborters from pre and post immunization. Healthy (male and females) controls were screened for
the presence of mixed lymphocyte reaction blocking antibodies. The standard mixed lymphocyte
reaction technique was used to evaluate the inhibitory effect of serum in the mixed lymphocyte
reaction. Each serum was tested for cytotoxic antibodies. Immunoglobulin G and its isotypes were
isolated according to the standard protocol.
Results: In the present study we have observed that there was significant inhibition of proliferation
response when immunoglobulin G from different trimesters of pregnancy were added to one way
mixed lymphocyte reaction or to phytohemagglutinin activated lymphocyte proliferation assay.
Similar pattern was seen when immunoglobulin G isolated from adequately immunized women with
recurrent spontaneous abortion was used. It was further confirmed that amongst all the isotypes
of immunoglobulin G, only immunoglobulin G-3 was found to be positive for the inhibitory effect.
Conclusions: Present study indicates that mixed lymphocyte reaction blocking antibodies are
immunoglobulin G-3 in nature. It is developed during pregnancy and also after immunotherapy in
women with recurrent spontaneous abortion who subsequently have the successful pregnancy.
Background
Recurrent spontaneous abortion (RSA) is defined as the
loss of three or more consecutive pregnancies prior to 20
weeks of gestation. In a large number of patients the un-
derlying cause of pregnancy loss often remains unclear
[1,2]. This may be due to anatomical uterine defects, chro-
mosomal defects, parental chromosomal rearrangements,
gene mutations, endocrine factors, sub clinical infections,
environmental toxins, collagen vascular diseases, auto im-
mune factors, and psychological trauma or stress. Howev-
er, in most of the women (1% – 2%) who experience
recurrent miscarriage, no cause can be identified.
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Alloimmune mechanisms that prevent mothers from de-
veloping immunological responses essential for the sur-
vival of the semiallogeneic pregnancy have been proposed
as the cause of 50% of all such losses. The maternal recog-
nition of paternally derived foetal antigens has been well
documented [3], and the presence of circulating antipater-
nal antibodies provides unequivocal evidence of a mater-
nal immune response to the allogenic pregnancy. In
contrast to allograft transplantation, paternal histocom-
patibility antigens expressed on the placenta elicit only
limited T cell immuno-reactivity [4]. The immunoglobu-
lins (IgGs) generated during pregnancy have been charac-
terized as asymmetrically glycosylated antibodies [5–7].
We have reported in our earlier studies that significant lev-
els of mixed lymphocyte reaction blocking antibodies
(MLR-Bf) production by paternal lymphocytes immuni-
zation in women with RSA, leads to successful pregnancy
[8]. In the present study an attempt has been made to
characterize the MLR-Bf in the total IgG fraction from dif-
ferent gestational windows of pregnancy and also in RSA
patients before and after immunization against their hus-
band's lymphocytes.
Methods
Serum samples were obtained from individuals of differ-
ent groups (Table 1). All individuals gave their consent to
participate in the study, and the protocol followed was ap-
proved by the institutes ethical committee. These groups
included 40 women of different stages of pregnancy (10
each in Ist, IInd, IIIrd trimesters and post delivery period),
20 women with RSA (10 each of pre and post immuniza-
tion), 10 healthy males and 10 unmarried non-pregnant
females. All participants were screened for the presence of
MLR-BF. Serum samples were separated from non
heparinized peripheral blood under aseptic conditions
further these samples were heat inactivated. After heat in-
activation each serum sample was aliquoted. One aliquot
was added to a panel of three peripheral blood lym-
phocytes (PBL) activated by PHA (phytohemagglutinin).
A second aliquot was added to one way mixed lym-
phocyte reaction (MLR). The dilution factor used was
50% volume by volume.
Immunological parameters
Peripheral blood lymphocytes were prepared by density
gradient centrifugation on ficoll-hypaque. For isolation of
T cells, PBL were incubated in plastic dishes at 37°C, 5%
CO2 for 12 hrs then passed through nylon wool columns.
Responders and stimulators from unrelated individuals
were chosen so that there was at least one human leuko-
cyte antigen (HLA) class I and one HLA DR antigen mis-
match was found between them. Irradiated stimulator
cells (2800 rads) were cultured in round bottomed 96
well plates with the responder cell in a ratio of 1:1 and a
concentration of 106 cells/ml. Plates were kept at 37°C in
a 5% CO2 atmosphere. Proliferation was measured at day
5 with (H3) thymidine incorporation in the last 18 hrs be-
fore harvesting. The percentage (%) of inhibition was cal-
culated by the following formula:
Cpm = count per minute
MLR = mixed lymphocyte reaction
Cytotoxic antibody determination
The percentage of panel reactive antibodies (PRA) was
evaluated against a panel of 50 individuals at room
temperature using the standard NIH lymphocytotoxicity
test. Sera were also tested on autologous cells to determine
auto reactivity, and pretreated with dithiothreitol to dif-
Table 1: Demographic profile
Different group of 
subjects
Number Age
(median; IQR)
Week of current 
pregnancy
(median; IQR)
Week of abortion
(median; IQR)
Ist trimester 10 26; 17–31 10; 6–11 Nil
IInd trimester 10 29; 20–30 19; 12–24 Nil
IIIrd trimester 10 28; 27–32 29; 23–29 Nil
Post delivery period 10 27; 21–27 Nil Nil
Pre immunized RSA 
Women
10 23; 21–30 Nil 8; 5–11
Post immunized RSA 
Women
10 24; 21–31 Nil 12; 8–16
Healthy males 10 25; 19–28 Nil Nil
Unmarried females 10 24; 20–28 Nil Nil
* Values are expressed in median and interquartile range (IQR).
% Inhibition
Cpm in test MLR
Cpm in control MLR
=− × 11 0 0BMC Pregnancy and Childbirth 2003, 3 http://www.biomedcentral.com/1471-2393/3/2
Page 3 of 7
(page number not for citation purposes)
ferentiate IgG from IgM mediated cytotoxicity. A standard
micro lymphocytotoxicity test was used to determine cy-
totoxicity against specific target cells. These cells were
same which were used as stimulators in the MLR or in the
PHA stimulation test. The same method was used to deter-
mine presence of cytotoxic antibodies in pooled IgG and
its isotypes using its dilution up to the 1: 8 from its origi-
nal concentration (10 mg/ml) in each test. If the sera con-
tained lymphocytotoxic antibodies these antibodies were
absorbed by using platelets.
Isolation and purification of IgG and its isotypes from pa-
tient's sera
10 individuals each from Ist, IInd and IIIrd trimester, post
delivery and post immunotherapy were taken from those
subjects who were positive for MLR-Bf activity. Each se-
rum was centrifuged for 20 min at 10,000 × g. An ammo-
nium sulphate saturated solution was added to the serum
(60%w/v) and incubated for 2 hrs so that IgG was com-
pletely precipitated. After centrifugation for 20 min at
10,000 × g the pellet was resuspended in ammonium bi-
carbonate buffer and dialyzed against the same buffer.
The serum was separated and purification of IgG was car-
ried out. IgG was also isolated from 10 males, 10 women
with RSA and 10 unmarried non-pregnant females (who
had no MLR-Bf activity). IgG fraction was prepared inde-
pendently from each individual. Dialyzed product was
fractionated on protein A coupled cyanogen bromide ac-
tivated sepharose 4B columns.
Purity of the preparations was assessed by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
with standard molecular weight marker and purified hu-
man IgG as well as enzyme linked immunosorbant assay
(ELISA) by using monoclonal antibodies directed against
IgG. Further all the isotypes of IgG (IgG1, IgG2, IgG3 and
IgG4) were separated on a protein A coupled cyanogen
bromide activated sepharose 4B columns. ELISA was used
to detect the IgG isotypes in each peak. Monoclonal anti-
bodies directed against IgG1, IgG2, IgG3 and IgG4 were
used in each ELISA. Each IgG fraction was lyophilized and
the protein content was measured.
Statistical tests
Results were expressed as median and interquartile range
(IQR). To compare proliferation indices between different
groups, the Mann-Whitney test was employed as the sam-
ple size was small in each group. However data from indi-
vidual experiments were measured by analysis of variance
(ANOVA) and Bonferroni's multiple comparison test. A
value of p < 0.05 was considered as statistically significant.
Results
Effect of neat serum on Lymphocytes
To evaluate the inhibitory effect of serum we carried out
some independent experiments with each serum from dif-
ferent groups as mentioned in the material methods sec-
tion. Serum was added at 0 hr of culture. All the serum
samples which inhibited the peripheral blood lym-
phocytes proliferation in primary MLR were considered as
MLR-Bf positive serum. The significance of inhibition of
the mixed lymphocytes reaction was compared with nor-
mal pooled AB (non cytotoxic) serum. The differences
were statistically significant (P < 0.001).
On the basis of this inhibitory mechanism, we further in-
vestigated the effect of these sera on PHA stimulated cells
of the person's own PBL and unrelated PBL separated
from three normal male controls. These were also used as
stimulators in the MLR assay. All the sera having inhibito-
ry activity inhibited unrelated PBL responses (2456 ± 250
cpm) but failed to inhibit their own cellular response to
PHA (30, 462 ± 1562 cpm). This indicated that inhibitory
effect was not against the autologous cells.
Further, to examine the inhibitory effect of purified IgG
we treated half of the stimulator cells with the inhibitory
IgG for 4 hrs at 4°C and washed the cells for three times,
mixed with untreated homologous stimulator PBL cells
before using them in MLR. Pre incubated stimulator cells
with the patient's sera were added to fresh stimulator PBL
cells in the ratio of 1: 1 in MLR cultures. Under these con-
ditions, values of (H3) thymidine uptake after 50/50 mix
of pre-incubated and freshly isolated stimulator cells
(32506 ± 3217 cpm) were not different from normal con-
trols (33617 ± 2527 cpm, p > 0.05). In another set of ex-
periments, after the addition of cells, harvesting was
carried out at 2nd and 4th day from the primary MLR cul-
tures to allogenic T cell lines, the allogenic cell prolifera-
tion were 21973 ± 1819 cpm and 20521 ± 2017 cpm.
These results indicated that the inhibition of proliferation
in MLR by women's sera is not due to the generation of
suppressor cells.
Determination of the inhibitory fraction in the sera of 
pregnant and post immunized women with RSA
We further examined the blocking activity present in IgM
and IgG fractions. The results of percent inhibition by
women s sera (WS) IgG and IgM on primed and unprimed
cell proliferation to alloantigens and PHA was analyzed.
WS IgG inhibited autologous cell proliferation in the MLR
system by 68.3 ± 3.19%. Inhibition was found when we
used WS to check the third party proliferation (59 ±
3.08%) but to a lesser extent and failed to inhibit
autologous cell proliferation (3.6 ± 4.16%). Fresh PBL
proliferation to PHA was inhibited by WS IgG to 61.3 ±
7.4%. WS IgM did not possess any inhibitory effect onBMC Pregnancy and Childbirth 2003, 3 http://www.biomedcentral.com/1471-2393/3/2
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both MLR and PHA stimulations. These results revealed
that the antimitogenic effect was present in the IgG and
not in the IgM fraction. To further determine whether cy-
totoxic antibodies were responsible for the potent antim-
itogenic effect present in the sera, we compared the
inhibitory effect before and after removal of lymphocyto-
toxic antibodies against HLA class I antigens by platelet
absorption. These were removed from 5 WS, 3 from differ-
ent trimesters of pregnancy and 2 from post immunized
women with RSA. The platelet-adsorbed sera (AS) were
tested independently on autologous proliferation to al-
loantigens from control (husband's AS) stimulator cells.
They were also tested on the same donor (AS) cellular pro-
liferation to PHA.
Inhibitory action of IgG and its isotypes on cell function
IgG and its each isotype purified from pooled sera from 5
individuals were subjected to lymphocytotoxicity and
blocking activity. Pooled IgG1, IgG2, IgG3 and IgG4 frac-
tions contained significant lymphocytotoxic activity at a
serial dilution of 1:64 (neat concentration 10 mg/ml)
against a panel of 50 T cells and 50 B cells. It was observed
that IgG1, IgG2 and IgG4 showed 50–80% cytotoxicity re-
spectively. However, in IgG3 fraction it was only 3%. After
determination of these lymphocytotoxicity, IgG1, IgG2,
IgG3 and IgG4 were further individually tested for block-
ing activity.
When fractionated IgG and its isotypes (IgG1, IgG2, IgG3
and IgG4) from different stages of pregnancy (Ist, IInd, II-
Ird trimester and post delivery period) and RSA women
(pre and post immunization) was added (10–50 µg/µl) at
0 hr of culture and measured its inhibitory activity against
the base line data (results not shown). Our results (Table
2 and 3) revealed that PHA and MLR proliferation was sig-
nificantly inhibited (F = 56.2, P < 0.001), in the presence
of whole IgG and IgG3 separated from all the stages of
pregnancy (Ist, IInd and IIIrd trimester) and post immu-
nized RSA women. No inhibition was found with the ad-
dition of IgG and its isotypes fractionated from pre
immunized RSA women, normal male and normal un-
married non-pregnant females.
Determination of antibody 2 and antibody 3 activity in the 
inhibitory IgG3 fraction
Since IgG3 fraction did not contain significant cytotoxic
reactivity but had a significant antimitogenic activity it
was tested for its capacity either to block or to enhance the
antibody I from IgG1, IgG2 and IgG4 fractions that con-
tained antibody I reactivity. The addition of three serial di-
lutions of IgG3 did not change the lymphocytotoxic titers
present in either IgG1, IgG2 or IgG4 fractions against a
known panel of T and B cell targets (data not shown)
which demonstrates absence of anti-idiotypic activity in
the pooled IgG3 fraction.
Discussion
The present study was carried out to characterize the MLR-
Bf present in normal pregnancy and also developed after
immunotherapy. To test this we isolated IgG fractions
from women having MLR-Bf in their sera (normal preg-
nancy) and from post immunized RSA women having
MLR-Bf in their sera and added to the cells stimulated by
PHA. The same sera were also added to one way MLR. Our
initial results demonstrated that the proliferation of cells
was significantly less in the presence of this fraction. To
find out the specific isotype of IgG which may be inhibi-
tory in nature we isolated and purified various isotypes of
IgG. These fractions were again added to the PHA
activated lymphocyte proliferation assay (LTT) and also to
Table 2: Stimulation index (SI) of MLR-Bf significant IgG and its isotypes
Different group of 
subjects
Proportionate change in the SI of IgG and its isotypes in terms of interquartile range (IQR)
IgG IgG1 IgG2 IgG3 IgG4
Ist trimester 25(14–27) 76(24–80) 68(42–82) 9(7–22) * 47(28–69)
IInd trimester 29(11–31) 82(44–84) 51(39–68) 7(6–34) * 79(65–92)
IIIrd trimester 35(17–38) 68(37–79) 69(57–82) 11(5–33) * 71(38–102)
Post delivery period 42(11–45) 57(39–61) 47(37–61) 41(23–57) 54(46–81)
Pre immunized RSA 
Women
38(28–56) 43(26–63) 64(29–71) 37(26–69) 66(33–87)
Post immunized RSA 
Women
21(19–28) 62(49–83) 72(39–77) 8(5–24) * 52(37–69)
Healthy male 52(46–71) 57(39–69) 48(34–56) 61(46–71) 41(39–58)
Unmarried females 83(39–86) 54(49–67) 65(43–73) 49(40–78) 61(43–99)
Values given in the table are calculated as stimulation index (SI) against the base line measurement and shown as median and interquartile range 
(IQR), n = 10. * P < 0.001.BMC Pregnancy and Childbirth 2003, 3 http://www.biomedcentral.com/1471-2393/3/2
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one way MLR. Significant inhibition in the proliferation
was observed (F = 56.2, P < 0.001) in the presence of IgG3
in comparison to IgG1, IgG2 and IgG4. Our results show
that blocking activity is targeted to the unprimed T cell re-
sponse which is due to alloantigens. The antimitogenic ef-
fect is most likely due to the binding with foreign HLA
class II antigens present on cells.
However, it is difficult to ascertain the exact site of action
of the inhibitory IgG fraction. These antibodies are very
likely synthesized systemically and act at the local level
(placenta), blocking placental antigens and preventing
immunological attack by maternal natural killer cells and
cytotoxic lymphocytes. It has been reported that women
with RSA had significantly lower levels of asymmetric IgG
as compared to controls [9,10]. These antibodies show
suppressive mechanism hence may be of the same nature
as the blocking antibodies. It has been shown by a
number of investigators that MLR-Bf is present during
normal pregnancy while it is absent or very low in women
with RSA [11–13]. It is argued that these factors may play
a protective role perhaps by blocking the damaging effect
of maternal lymphocytes
Some investigators have questioned the role of blocking
antibodies in the maintenance of normal pregnancy
[14,15]. Their studies suggested that alterations in the ra-
tio of T helper 1 (Th1) cells to T helper 2 (Th2) cells play
an important role in immune modulation. Other studies
have demonstrated the indication of asymmetric IgG syn-
thesis by a progesterone induced blocking factor (PIBF)
[16]. PIBF has been shown to influence the balance of Th
1 cells to Th 2 cells which subsequently alters cytokine ra-
tios and decrease the cell mediated immune response dur-
ing pregnancy [17]. Thus the production of PIBF early in
pregnancy may play a role in activation of cellular and hu-
moral immune system to prevent the immunologic at-
tack. However, the exact role is still controversial.
Tamura et al. [11] have reported that the presence of MLR-
Bf during the Ist pregnancy makes a significant contribu-
tion in the success of 2nd pregnancy. Ramhorst et al. [12]
have shown that the blocking factor plays an important
role in women with RSA undergoing immunotherapy. We
recently demonstrated that MLR-Bf developed with the
husband's lymphocytes, during pregnancy and post im-
munotherapy in RSA women, is important for the success
of human pregnancy [8]. Gatenby [18] have reported that
development of MLR-Bf might be because of prolonged
maintenance of CD8+ suppressor T cells, which suppress
the immune mechanisms that are required for the main-
tenance and the outcome of successful pregnancy. Our re-
sults definitely show that the presence of MLR-Bf during
pregnancy and after immunotherapy is a good prognostic
marker for the success of pregnancy. The success of preg-
nancy in the face of potential maternal immune reactions
has been largely attributed to the placenta, which appears
to serve as an immunological barrier. The ability of the
trophoblast tissue to survive in the conditions of allograft
rejection was initially attributed to the non-antigenic na-
ture. But later it was shown that the trophoblast expresses
major histocompatibility complex (MHC) antigens on the
surface[19]. This can lead to alloantibody formation dur-
ing normal pregnancy. Alloimmunity has been indicated
Table 3: Percentage inhibition (%) of MLR-Bf significant IgG and its isotypes
Different 
group of 
subjects
Proportionate change in percentage inhibition of MLR-Bf significant IgG and its isotypes in terms of interquartile range (IQR)
IgG IgG1 IgG2 IgG3 IgG4
W × H 
(1:2)
H × W 
(2:1)
W × H 
(1:2)
H × W 
(2:1)
W × H 
(1:2)
H × W 
(2:1)
W × H 
(1:2)
H × W 
(2:1)
W × H 
(1:2)
H × W 
(2:1)
Ist trimester 39 (35–67) 26 (21–63) 22 (18–28) 24 (15–26) 17 (-11–37) 21 (7–42) 68 (61–68) * 64 (60–63) * 19 (17–45) 17 (11–21)
IInd trimester 42 (28–71) 39 (35–64) 18 (15–24) 17 (14–19) 12 (3–33) 11 (9–15) 61 (63–70) * 62(61–67) * 29 (-14–33) 4 (-17–8)
IIIrd trimester 27 (21–62) 35 (27–67) -14 (-27–9) 13 (-8–27) 15 (9–23) 17 (14–21) 67 (61–82) * 71(62–76) * 15 (15–28) 13 (9–16)
Post delivery 
period
44 (20–68) 25 (23–68) 17 (-3–20) 15 (10–30) 5 (-9–19) 11 (7–31) 47 (14–47) 41(23–52) 8 (4–17) 11 (6–22)
Pre immunized 
RSA Women
34 (28–47) 28 (23–61) 6 (-12–9) -6 (-11–2) 2 (24–11) 5 (-22–7) 43 (17–37) 38(21–36) 6 (-12–6) 8 (5–19)
Post immunized 
RSA Women
51 (44–69) 60 (57–73) -7 (-16–7) 4 (-12–6) 12 (6–31) 21 (11–29) 67 (64–82) * 67(62–71) * 21 (19–26) 15 (10–30)
Healthy male -9 (-21–2) -17 (-8–4) -17 (-19–2) -8 (-11–3) -15 (-27–5) 4 (-17–2) -11 (-19–9) -12(-18–7) -6 (-29–4) -11 (-18–19)
Unmarried 
females
-17 (-24–6) -23 (-35–2) -7 (-11–3) 3 (-7–10) -5 (-17–4) 9 (-21–12) 15 (-11–3) 12(-6–17) 14 (11–22) 25 (24–27)
1:2 (non irradiated cells of control female × irradiated cells of control male), 2:1 (non irradiated cells of control male × irradiated cells of control 
female) W = wife, H = husband. Values given in the table are calculated as percentage inhibition (%) against the base line measurement and shown 
as median and interquartile range(IQR), n = 10.*P < 0.001BMC Pregnancy and Childbirth 2003, 3 http://www.biomedcentral.com/1471-2393/3/2
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in several studies by the association of habitual abortion
with an increased sharing of human leukocyte antigens
that may prohibit the mother from making blocking anti-
bodies [20,21].
Our results indicated that a significant amount of MLR-Bf
developed during pregnancy and after paternal lym-
phocyte immunotherapy in women with RSA is of IgG 3
nature, which may play an important role in the success of
pregnancy in these women. Zenclussen et al. [10] have
demonstrated that women undergoing immunotherapy
expressed higher percentage of asymmetric IgG antibod-
ies, which play a protective role during pregnancy.
It has been observed that inhibition of T cell activation is
caused by the antibodies against the α-3 domain of the
human MHC class I molecule. Stach and Rowley [22]
have demonstrated that the inhibitory fraction is associat-
ed with transforming growth factor-beta (TGF-β). They
have suggested that immunoglobulin – TGF-β conjugate
is taken up by the antigen presenting cells by FC depend-
ent mechanisms. It is conceivable that the inhibitory IgG
preparations employed in our study contain antibody –
cytokine conjugates that target and are internalized by an-
tigen presenting cells following binding to MHC encoded
public epitopes of class I or II molecules expressed on the
allogenic cells. It may be postulated that absence of these
inhibitory antibodies in women with RSA may prevent
the generation of suppressor systems, which are required
for the survival of the foetus as an allograft.
Conclusion
Our results clearly demonstrated that MLR-Bf in the shape
of IgG3 fraction was generated during pregnancy but ab-
sent in women with RSA, unmarried non-pregnant fe-
males and normal healthy males. Upon immunotherapy
this fraction (IgG3) was also developed in women with
RSA and played an important role in the maintenance of
pregnancy.
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